Harbour Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Harbour Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,925	Closed	-$289K	–	310
2025 Q1	$289K	Buy	+4,925	New	+$518K	0.07%	228
2023 Q3	–	Sell	-3,140	Closed	-$356K	–	278
2023 Q2	$356K	Hold	3,140	–	–	0.11%	176
2023 Q1	$432K	Buy	3,140 +260	+9%	+$33.7K	0.13%	150
2022 Q4	$360K	Buy	+2,880	New	+$334K	0.12%	158
2020 Q4	–	Sell	-8,050	Closed	-$1.13M	–	168
2020 Q3	$1.13M	Buy	8,050 +60	+0.8%	+$9.12K	0.41%	70
2020 Q2	$1.28M	Hold	7,990	–	–	0.52%	60
2020 Q1	$782K	Sell	7,990 -3,528	-31%	-$403K	0.4%	76
2019 Q4	$1.49M	Sell	11,518 -1,802	-14%	-$182K	0.57%	64
2019 Q3	$1M	Buy	13,320 +2,740	+26%	+$324K	0.42%	79
2019 Q2	$1.61M	Buy	10,580 +2,582	+32%	+$314K	0.69%	54
2019 Q1	$953K	Sell	7,998 -660	-8%	-$84.9K	0.42%	80
2018 Q4	$945K	Buy	8,658 +83	+1%	+$10.4K	0.47%	78
2018 Q3	$1.39M	Buy	8,575 +320	+4%	+$43.7K	0.56%	56
2018 Q2	$1.11M	Buy	8,255 +5,225	+172%	+$493K	0.48%	80
2018 Q1	$224K	Buy	+3,030	New	+$202K	0.1%	227
2016 Q3	–	Sell	-17,550	Closed	-$335K	–	274
2016 Q2	$335K	Hold	17,550	–	–	0.19%	168
2016 Q1	$343K	Buy	+17,550	New	+$307K	0.2%	156

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Harbour Capital Advisors's SRPT Position: Q2 2025 in Review

Harbour Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 4,925 shares — an estimated $289K sold.

Harbour Capital Advisors first reported a position in SRPT in Q1 2016 and held it in 17 quarters. The position peaked at $1.61M in Q2 2019. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Harbour Capital Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Harbour Capital Advisors sold 4,925 Sarepta Therapeutics shares in Q2 2025, an estimated $289K.
Harbour Capital Advisors first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 17 quarters.
Harbour Capital Advisors's Sarepta Therapeutics position peaked at $1.61M in Q2 2019.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Harbour Capital Advisors's 13F filing for Q2 2025, filed 11 Jul 2025.